RP-6306 NEW
| Price | $133 | $329 | $488 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: RP-6306 | CAS No.: 2719793-90-3 |
| Purity: 99.28% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | RP-6306 |
| Description | Lunresertib (RP-6306) is a potent, selective, and orally active PKMYT1 inhibitor with an IC50 of 14 nM. Lunresertib (RP-6306) inhibits the growth of CCNE1-amplified tumor cells in several preclinical xenograft models. |
| In vitro | METHODS: HCC1569 breast cancer cell line was treated with lunresertib (RP-6306) (63, 125, 250, 500 nM) to assess whether PKMYT1 inhibition leads to DNA damage in CCNE1-high cells by monitoring γH2AX levels using quantitative image-based flow cytometry. RESULTS Treatment with lunresertib (RP-6306) induced pan-γH2AX in the HCC1569 breast cancer cell line, suggesting that tumor-derived CCNE1 amplification also renders cells susceptible to DNA damage induction following PKMYT1 inhibition. [1] |
| In vivo | METHODS: lunresertib (RP-6306) (3, 10 and 60 mg/kg, oral, daily) was used to treat CCNE1-amplified ovary xenograft model (OVCAR3) mice, and tumor growth in the mice was observed. RESULTS lunresertib (RP-6306) inhibited tumor growth in OVCAR3 mice in a statistically significant concentration-dependent manner. [2] |
| Storage | keep away from direct sunlight,keep away from moisture,store at low temperature | Shipping with blue ice. |
| Solubility Information | DMSO : 45.0 mg/mL (138.7 mM), Sonication is recommended. |
| Keywords | RP 6306 | RP6306 | RP-6306 |
| Inhibitors Related | ZN-c3 | GSK-1520489A | PD0166285 | ZNL 02-096 | Adavosertib | PD 407824 | Debio-0123 | WEE1-IN-3 | PD173952 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2120.00/25mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1kg |
VIP4Y
|
XINXIANG RUNYU MATERIAL CO., LTD.
|
2024-01-22 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY